2026-04-17T23:44:21Zhttps://recercat.cat/oai/request
oai:recercat.cat:10256/218522024-06-18T12:38:21Zcom_2072_452955com_2072_2054col_2072_453068
RECERCAT author Solans Margalef, Marta author Sanvisens, Arantza author Ameijide, Alberto author Merino, Susana author Rojas Martín, María Dolores author Alemán, Araceli author Banqueri, Emilia author Chico, Matilde author Marcos, Ana Isabel author Castro, Visitación de author Gil, Leire author López de Munain Marqués, Arantza author Puigdemont, Montserrat author Sánchez, Maria-José author Perucha, Josefina author Ruiz-Armengol, Patricia author Chirlaque, María Dolores author Guevara, Marcela author Carulla, Marià author Marcos-Gragera, Rafael 2024-06-18T12:38:21Z 2024-06-18T12:38:21Z 2022-01-10 http://hdl.handle.net/10256/21852 Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002–2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASRE), incidence trends, and estimates for 2021 were calculated. ASRE per 100,000 inhabitants was 5.14 (95% CI: 5.00–5.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59–4.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79–4.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78–0.88) for MDS/MPN, 0.35 (95% CI: 0.32–0.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53–0.62) for not-otherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs)This work was partially funded by the Josep Carreras Leukaemia Research Institute (Grant No.: FIJC1100); the Ministry of Science, Innovation and Universities, Carlos III Health Institute (ISCIII), Spain (Grant No.: PI15/00966); the Agency for Management of University and Research Grants, Government of Catalonia (Grant No.: 2017SGR00733); the CIBER of Epidemiology and Public Health (CIBERESP) (‘Cohort-Real World Data’ subprogram) Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Tumors -- Espanya Tumors -- Spain Càncer -- Estadístiques Cancer -- Statistics Leucèmia mieloide Myeloid leukemia Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion peer-reviewed